|
![]() |
|||
|
||||
OverviewThe discovery of the anti-tumour activity of cisplatin in 1965, and its subsequent introduction into clinical trials in 1971, was the catalyst for a major research effort into the potential of metal compounds in cancer therapy. This book provides a discussion of metal compounds in cancer therapy. This book should be of interest to research workers in the pharmaceutical industry, particularly tumour pharmacologists, tumour biologists, medicinal chemists and oncologists. Full Product DetailsAuthor: S. P. FrickerPublisher: Chapman and Hall Imprint: Chapman and Hall Edition: and ed. Volume: v. 1 Weight: 0.480kg ISBN: 9780412542800ISBN 10: 0412542803 Pages: 304 Publication Date: November 1994 Recommended Age: Up to 18 years Audience: Professional and scholarly , Professional & Vocational Format: Hardback Publisher's Status: Active Availability: Available To Order ![]() We have confirmation that this item is in stock with the supplier. It will be ordered in for you and dispatched immediately. Table of ContentsIntroduction, S.P. Fricker. Platinum Anti-Cancer Drugs L.R. Kelland. Gold, F. Shaw III. Ruthenium Compound in Cancer Therapy, G. Sava. Rhodium, Iridium and Palladium Compounds as Experimental Anticancer Drugs, G. Buckley. Organometallic Titanium, Vanadium, Niobium, Molybdenum and Rhenium Complexes - Early Transition Metal Anti-Tumour Drugs, P. Kopf-Maier and H. Kopf. Anti-tumour Activity of Tin Compounds, A.J. Crowe. Gallium Compounds in Cancer Therapy, P. Collery. Bleomycin and Metal Interactions, J.M.C. Gutteridge. The In Vivo use of Metallic Radioisotopes in Cancer Detection and Imaging, D.J. Hnatowich.ReviewsAuthor InformationTab Content 6Author Website:Countries AvailableAll regions |